Affordable Access

deepdyve-link
Publisher Website

Long noncoding RNA FEZF1-AS1 in human cancers.

Authors
  • Zhou, Yuanshi1
  • Xu, Shuwan1
  • Xia, Haoming1
  • Gao, Zewei1
  • Huang, Rongju1
  • Tang, Enyu1
  • Jiang, Xingming2
  • 1 Department of HPB Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu-ro, Harbin 150086, China. , (China)
  • 2 Department of HPB Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu-ro, Harbin 150086, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Clinica chimica acta; international journal of clinical chemistry
Publication Date
Jul 02, 2019
Identifiers
DOI: 10.1016/j.cca.2019.07.004
PMID: 31276636
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Long noncoding RNAs (lncRNAs) have been shown to play key roles in various human tumors. Ectopic expression of the lncRNA FEZ finger zinc 1 antisense 1 (FEZF1-AS1) have been reported in different cancers, including colorectal cancer, gastric neoplasia, hepatocellular carcinoma and so on. Summarizing all literature correlated with FEZF1-AS1, it is obvious that FEZF1-AS1 is mainly involved in tumorigenesis and progression through competing endogenous RNA (ceRNA) which sponges tumor-suppressive microRNA (miRNA) and recruiting mechanism. Moreover, the aberrant expression of FEZF1-AS1 is related to clinical features of patients with cancers, and regulates cellular proliferation, anti-apoptosis, invasion and metastasis through diverse underlying mechanisms. The role of FEZF1-AS1 in carcinogenesis and progression suggests that it may be a potential diagnostic biomarker or a novel therapeutic target for cancers. Copyright © 2018. Published by Elsevier B.V.

Report this publication

Statistics

Seen <100 times